医学
贝伐单抗
阿替唑单抗
内科学
打开标签
肿瘤科
宫颈癌
化疗
癌症
临床试验
免疫疗法
彭布罗利珠单抗
作者
Ana Oaknin,Laurence Gladieff,Jerónimo Martínez-García,Guillermo Villacampa,Munetaka Takekuma,Ugo De Giorgi,Kristina Lindemann,Linn Woelber,Nicoletta Colombo,Linda Duska,Alexandra Léary,Ana Godoy-Ortíz,Shin Nishio,Antoine Angelergues,María Jesús Rubio,Lorena Fariñas-Madrid,Satoshi Yamaguchi,Domenica Lorusso,Isabelle Ray‐Coquard,Luís Manso
出处
期刊：The Lancet
[Elsevier BV]
日期：2023-12-01
卷期号：403 (10421): 31-43
被引量：203
标识
DOI：10.1016/s0140-6736(23)02405-4
摘要
The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10-GEICO 68-C-JGOG1084-GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
cdercder
Nole
X的三次方
Kao
DW
dde
DOC_XIONG
犹豫的大碗
呵呵呵
Dean
一一一
GingerF
aaaa
aajhajkahna
xing_xing
无极微光
zhangchi
初景
ASH
殷勤的紫槐
皖公网安备34019202002308
